BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zaccherini G, Tufoni M, Iannone G, Caraceni P. Management of Ascites in Patients with Cirrhosis: An Update. J Clin Med 2021;10:5226. [PMID: 34830508 DOI: 10.3390/jcm10225226] [Reference Citation Analysis]
2 Fan K, Zan X, Zhi Y, Yang Y, Hu K, Zhang X, Zhang X, Zhao S, Chen K, Gong X, Tian R, Zhang L. Immune response gene 1 deficiency impairs Nrf2 activation and aggravates liver fibrosis in mice. Biochemical and Biophysical Research Communications 2022;607:103-9. [DOI: 10.1016/j.bbrc.2022.03.110] [Reference Citation Analysis]
3 Lamatsch S, Sittner R, Tacke F, Engelmann C. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov 2021;:1-10. [PMID: 34971342 DOI: 10.1080/17460441.2022.2020755] [Reference Citation Analysis]
4 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
5 Jalan R, Szabo G. New concepts and perspectives in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S1-2. [PMID: 34039481 DOI: 10.1016/j.jhep.2020.12.008] [Reference Citation Analysis]
6 de Jong LA, van Schoonhoven AV, Hofstra HS, Postma MJ, van Hoek B. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands. J Med Econ 2021;24:1149-63. [PMID: 34629016 DOI: 10.1080/13696998.2021.1983291] [Reference Citation Analysis]
7 Lu Y, Li M, Zhou Q, Fang D, Wu R, Li Q, Chen L, Su S. Dynamic network biomarker analysis and system pharmacology methods to explore the therapeutic effects and targets of Xiaoyaosan against liver cirrhosis. J Ethnopharmacol 2022;294:115324. [PMID: 35489663 DOI: 10.1016/j.jep.2022.115324] [Reference Citation Analysis]